Journal article
Performance of the 2017 EUSTAR activity index in an scleroderma cohort
L Ross, W Stevens, M Wilson, M Huq, G Strickland, J Walker, J Sahhar, GS Ngian, J Roddy, P Youssef, S Proudman, M Nikpour
Clinical Rheumatology | SPRINGER LONDON LTD | Published : 2020
Abstract
Assessment of disease activity in systemic sclerosis (SSc) is limited by the absence of a fully validated, multisystem measure of disease activity. The European Scleroderma Trials and Research Group (EUSTAR) SSc activity index (EScSG-AI) was recently revised, and a validation study within the EUSTAR cohort was performed. In this study, we evaluated the performance of the revised EScSG-AI in an external Australian cohort. The association between the EScSG-AI and the physician global assessment of disease activity (PhGA), both collected prospectively at each annual visit over up to 12 years follow-up, was evaluated using Pearson’s correlation coefficient and Cohen’s kappa coefficient. Generali..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
Dr. Laura Ross is supported by a Musculoskeletal Australia PhD scholarship and an Australian Government Research Training Program Scholarship. Associate Professor Mandana Nikpour holds a National Health and Medical Research Council of Australia Fellowship (APP 1126370). The Australian Scleroderma Cohort Study is supported by the Actelion Australia, Scleroderma Australia, Scleroderma Victoria, Arthritis Australia, Musculoskeletal Australia, Scleroderma Clinical Trials Consortium (SCTC), St Vincent's Hospital Research Endowment Fund, Australian Rheumatology Association, philanthropic donations, GlaxoSmithKline, Roche, Pfizer, Bayer, CSL Biotherapies and Bristol-Myers Squibb.